Risk Factors for Plasmodium falciparum Recurrence in Artemether Lumefantrine Treated Population from Bushenyi District, Uganda

Background: Malaria remains a major Public health problem. In 2019, it was reported that Uganda accounts for 5 % of the total global cases of malaria related deaths after Nigeria and Democratic Republic of Congo.Various risk factors may be responsible for poor treatment outcomes. Thus the main aim of this study was to evaluate the Risk factors for Plasmodium falciparum recurrence in Artemether-lumefantrine treated population from Bushenyi district, Uganda. Methods: A descriptive cross-sectional study was conducted in four selected health centers of Bushenyi district, Uganda by using questionnaire, direct observations and laboratory based studies. Data analysis was done using statistical package for social sciences (SPSS version 23 windows) for descriptive statistics. Logistic regression analysis was done to evaluate the association between Plasmodium falciparum recurrence and associated risk factors. Results: Statistically independent predictor risk factors for Plasmodium falciparum recurrence at p<0.05 were; Previous Diagnosis used before the current artemether lumefantrine (AL) treatment (OR=11.864; 95% CI: 1.477-95.280; p=0.020), Sleeping with animals (OR=0.193; 95% CI: 0.075-0.894; P=00.032), Age (OR=1.435; 95% CI: 0.0825-0.975; p=0.040), Travelling outside the study area (OR=2.324; 95% CI: 0.050-0.699; p= 0.012), Weight (OR =1.543; 95% CI: 0.085-0.987; p= 0.002), Gametocytes on day 0 (OR =0.284; 95% CI: 0.0625-0.735; p= 0.032)9 Conclusions: Monitoring of transmission potentiality after Artemisinin combined therapies (ACTs) treatment is vital in the fight against malaria infection.

[1]  G. Milanez,et al.  The high risk of malarial recurrence in patients with Plasmodium-mixed infection after treatment with antimalarial drugs: a systematic review and meta-analysis , 2021, Parasites & vectors.

[2]  Jennifer L. Guler,et al.  Surveillance of Plasmodium falciparum pfcrt haplotypes in southwestern uganda by high‐resolution melt analysis , 2021, Malaria journal.

[3]  O. Doumbo,et al.  Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  L. Cui,et al.  Role of Plasmodium falciparum Kelch 13 Protein Mutations in P. falciparum Populations from Northeastern Myanmar in Mediating Artemisinin Resistance , 2020, mBio.

[5]  J. Kaewkungwal,et al.  Epidemiological profiles of recurrent malaria episodes in an endemic area along the Thailand-Myanmar border: a prospective cohort study , 2019, Malaria Journal.

[6]  J. Augereau,et al.  Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination , 2018, Parasite.

[7]  A. Aliero,et al.  Plasmodium falciparum Malaria Clinical and Parasitological Outcomes after In-vivo Artemether-Lumefantrine (AL) Treatment at Bushenyi District Uganda , 2018 .

[8]  L. Duchateau,et al.  Zooprophylaxis as a control strategy for malaria caused by the vector Anopheles arabiensis (Diptera: Culicidae): a systematic review , 2017, Infectious Diseases of Poverty.

[9]  N. Speybroeck,et al.  Micro-epidemiology and spatial heterogeneity of P. vivax parasitaemia in riverine communities of the Peruvian Amazon: A multilevel analysis , 2017, Scientific Reports.

[10]  A. Benito,et al.  Spatial clustering and risk factors of malaria infections in Bata district, Equatorial Guinea , 2017, Malaria Journal.

[11]  T. Horii,et al.  Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda , 2017, Malaria Journal.

[12]  N. White,et al.  The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread , 2017, FEMS microbiology reviews.

[13]  C. Obua,et al.  Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda , 2016, BMC Infectious Diseases.

[14]  M. Kulkarni,et al.  Plasmodium falciparum malaria parasitaemia among indigenous Batwa and non-indigenous communities of Kanungu district, Uganda , 2016, Malaria Journal.

[15]  C. Fontes,et al.  Factors associated with recurrent Plasmodium vivax malaria in Porto Velho, Rondônia State, Brazil, 2009. , 2014, Cadernos de saude publica.

[16]  O. Amodu,et al.  Factors Associated with a Poor Treatment Outcome among Children Treated for Malaria in Ibadan, Southwest Nigeria , 2014, Epidemiology Research International.

[17]  R. Cibulskis,et al.  World Malaria Report 2013 , 2014 .

[18]  L. Okell,et al.  Residual Plasmodium falciparum Parasitemia in Kenyan Children After Artemisinin-Combination Therapy Is Associated With Increased Transmission to Mosquitoes and Parasite Recurrence , 2013, The Journal of infectious diseases.

[19]  P. Kremsner,et al.  Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. , 2013, Trends in parasitology.

[20]  Y. Berhane,et al.  Travel history and malaria infection risk in a low-transmission setting in Ethiopia: a case control study , 2013, Malaria Journal.

[21]  R. Price,et al.  Early parasitological response following artemisinin-containing regimens: a critical review of the literature , 2013, Malaria Journal.

[22]  R. Hallett,et al.  Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications , 2012, The American journal of tropical medicine and hygiene.

[23]  S. Hoffman,et al.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.

[24]  Renuka Kunte,et al.  WHO Guidelines for the treatment of malaria , 2011 .

[25]  R. Price,et al.  Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  N. Speybroeck,et al.  Ranking Malaria Risk Factors to Guide Malaria Control Efforts in African Highlands , 2009, PloS one.

[27]  Stephane Proux,et al.  Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment , 2009, PloS one.

[28]  C. Whitty,et al.  Impact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidence , 2007, Malaria Journal.

[29]  A. Saul,et al.  Zooprophylaxis or zoopotentiation: the outcome of introducing animals on vector transmission is highly dependent on the mosquito mortality while searching , 2003, Malaria Journal.

[30]  J. Breman,et al.  The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. , 2001, The American journal of tropical medicine and hygiene.